The rates of complete remission/complete remission unknown (CR/CRu) were 88% for CHOP vs 62% for ABVD. Eighty percent of patients in the CHOP group had 3 or more risk factors compared with 40% in the ABVD group. No mortalities were reported in the CHOP group in contrast to the ABVD group, but event-free survival (EFS) was inferior with CHOP compared with ABVD. CHOP is a low-toxic treatment regimen—with risk factors—that appears to be an effective treatment for HL. The researchers concluded that additional studies are needed to evaluate the true merit of CHOP to replace ABVD as a standard of treatment.